Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Buy
62
BMRN Quote, Financials, Valuation and Earnings
Last price:
$66.64
Seasonality move
:
5.39%
Day range:
$65.25 - $67.09
52-week range:
$61.15 - $99.25
Dividend yield:
0%
P/E ratio:
39.90x
P/S ratio:
4.75x
P/B ratio:
2.35x
Volume:
439K
Avg. volume:
1.5M
1-year change:
-30.75%
Market cap:
$12.7B
Revenue:
$2.4B
EPS (TTM):
$1.67
Analysts' Opinion
-
Consensus RatingBiomarin Pharmaceutical has received a consensus rating of Buy. The company's average rating is a Buy based on 13 Buy ratings, 5 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $98.08, Biomarin Pharmaceutical has an estimated upside of 47.2% from its current price of $66.63.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $65.00 representing 100% downside risk from its current price of $66.63.
Fair Value
-
According to the consensus of 18 analysts, Biomarin Pharmaceutical has 47.2% upside to fair value with a price target of $98.08 per share.
BMRN vs. S&P 500
-
Over the past 5 trading days, Biomarin Pharmaceutical has underperformed the S&P 500 by -3.67% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Biomarin Pharmaceutical does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Biomarin Pharmaceutical has grown year-over-year revenues for 11 quarters straight. In the most recent quarter Biomarin Pharmaceutical reported revenues of $745.7M.
Earnings Growth
-
Biomarin Pharmaceutical has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Biomarin Pharmaceutical reported earnings per share of $0.55.
Enterprise value:
12.4B
EV / Invested capital:
2.06x
Price / LTM sales:
4.75x
EV / EBIT:
30.37x
EV / Revenue:
4.49x
PEG ratio (5yr expected):
0.34x
EV / Free cash flow:
41.09x
Price / Operating cash flow:
43.48x
Enterprise value / EBITDA:
24.40x
Gross Profit (TTM):
$2.2B
Return On Assets:
4.69%
Net Income Margin (TTM):
11.71%
Return On Equity:
6.29%
Return On Invested Capital:
5.27%
Operating Margin:
15.27%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $2B | $2.3B | $2.8B | $581.3M | $745.7M | |
| Gross Profit | $1.5B | $1.8B | $2.2B | $453.3M | $557.3M | |
| Operating Income | $5.7M | $177.8M | $312.4M | $73.7M | $113.9M | |
| EBITDA | $219.6M | $268M | $506.7M | $71.1M | $156.4M | |
| Diluted EPS | $0.42 | $0.77 | $1.67 | $0.21 | $0.55 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.7B | $2.3B | $2.7B | $3B | $3.1B | |
| Total Assets | $6.2B | $6B | $6.3B | $6.8B | $6.9B | |
| Current Liabilities | $854.7M | $514.9M | $521M | $1.2B | $715.7M | |
| Total Liabilities | $2.1B | $1.7B | $1.7B | $1.9B | $1.4B | |
| Total Equity | $4.1B | $4.3B | $4.6B | $4.9B | $5.4B | |
| Total Debt | $1.4B | $1.1B | $1.1B | $1.1B | $594.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $180.3M | $138.6M | $414.7M | $135.6M | $221.5M | |
| Cash From Investing | -$20.7M | -$101M | -$4.9M | -$45.8M | -$16.2M | |
| Cash From Financing | -$15.1M | -$18.7M | -$518.5M | -$788K | -$499.1M | |
| Free Cash Flow | $40.8M | $31.3M | $300.9M | $112.2M | $200.3M | |
BMRN
Sector
Market Cap
$12.7B
$46.1M
Price % of 52-Week High
67.13%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-30.75%
-30.52%
Beta (5-Year)
0.295
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$65.87
200-day SMA
Sell
Level
$78.72
Bollinger Bands (100)
Sell
Level
63.82 - 83.66
Chaikin Money Flow
Buy
Level
173.5M
20-day SMA
Buy
Level
$65.82
Relative Strength Index (RSI14)
Buy
Level
52.97
ADX Line
Buy
Level
10.02
Williams %R
Neutral
Level
-31.4721
50-day SMA
Buy
Level
$66.54
MACD (12, 26)
Sell
Level
-0.08
25-day Aroon Oscillator
Buy
Level
52
On Balance Volume
Neutral
Level
241.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (6.4102)
Buy
CA Score
(Annual)
Level (0.8417)
Sell
Beneish M-Score
(Annual)
Level (-2.193)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-2.2253)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
Stock Forecast FAQ
In the current month, BMRN has received 13 Buy ratings 5 Hold ratings, and 0 Sell ratings. The BMRN average analyst price target in the past 3 months is $98.08.
-
Where Will Biomarin Pharmaceutical Stock Be In 1 Year?
According to analysts, the consensus estimate is that Biomarin Pharmaceutical share price will rise to $98.08 per share over the next 12 months.
-
What Do Analysts Say About Biomarin Pharmaceutical?
Analysts are divided on their view about Biomarin Pharmaceutical share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Biomarin Pharmaceutical is a Sell and believe this share price will drop from its current level to $65.00.
-
What Is Biomarin Pharmaceutical's Price Target?
The price target for Biomarin Pharmaceutical over the next 1-year time period is forecast to be $98.08 according to 18 Wall Street analysts, 13 of them rate the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is BMRN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Biomarin Pharmaceutical is a Buy. 13 of 18 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BMRN?
You can purchase shares of Biomarin Pharmaceutical via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Biomarin Pharmaceutical shares.
-
What Is The Biomarin Pharmaceutical Share Price Today?
Biomarin Pharmaceutical was last trading at $66.64 per share. This represents the most recent stock quote for Biomarin Pharmaceutical. Yesterday, Biomarin Pharmaceutical closed at $66.63 per share.
-
How To Buy Biomarin Pharmaceutical Stock Online?
In order to purchase Biomarin Pharmaceutical stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
